EP300
Overview
Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL. These mutations impair histone acetylation, disrupt epigenetic gene regulation. This gene has some recurrent sites of mutations (hot spots), which typically impact its HAT domain, a region crucial for acetylating histones and non-histone proteins.1,2 Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.3
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| BL | 2 | relevance in BL not firmly established |
| DLBCL | 1 | high-confidence DLBCL gene |
| FL | 1 | high-confidence FL gene |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 4.62 |
| BL | Thomas cohort | 4.20 |
| BL | Panea cohort | 7.90 |
| DLBCL | GAMBL genomes | 11.85 |
| DLBCL | Schmitz cohort | 9.79 |
| DLBCL | Reddy cohort | 7.11 |
| DLBCL | Chapuy cohort | 8.12 |
| FL | GAMBL genomes | 12.47 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | No | No | 2.769 | 3.550 |
| DLBCL | No | No | 3.344 | 7.980 |
| FL | No | Yes | 15.586 | 7.719 |
[!NOTE] First described in DLBCL in 2011 by Pasqualucci L. First described in FL in 2011 by Morin RD
## EP300 Hotspots
| Chromosome | Coordinate (hg19) | ref>alt | HGVSp |
|---|---|---|---|
| chr22 | 41566459 | T>C | Y1446H |
| chr22 | 41566460 | A>G | Y1446C |
| chr22 | 41566460 | A>C | Y1446S |
| chr22 | 41566462 | A>T | I1447F |
| chr22 | 41566466 | T>G | F1448C |
| chr22 | 41566474 | C>T | H1451Y |
| chr22 | 41566476 | T>G | H1451Q |
| chr22 | 41566478 | C>T | P1452L |
| chr22 | 41566486 | C>G | Q1455E |
| chr22 | 41566487 | A>G | Q1455R |
| chr22 | 41566488 | G>T | Q1455H |
| chr22 | 41566495 | C>T | P1458S |
| chr22 | 41566495 | C>A | P1458T |
| chr22 | 41566496 | C>T | P1458L |
| chr22 | 41566511 | T>C | L1463P |
| chr22 | 41566511 | T>G | L1463R |
| chr22 | 41566519 | T>G | W1466G |
| chr22 | 41566519 | T>A | W1466R |
| chr22 | 41566519 | T>C | W1466R |
| chr22 | 41566520 | G>T | W1466L |
| chr22 | 41566521 | G>C | W1466C |
| chr22 | 41566522 | T>A | Y1467N |
| chr22 | 41566522 | T>C | Y1467H |
| chr22 | 41566522 | T>G | Y1467D |
| chr22 | 41566523 | A>G | Y1467C |
| chr22 | 41566523 | A>T | Y1467F |
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
References
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., Murty, V., Mullighan, C., Gaidano, G., Rabadán, R., Brindle, P., & Dalla-Favera, R. (2010). Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature, 471, 189 - 195. https://doi.org/10.1038/nature09730.
Cerchietti, L., Hatzi, K., Caldas-Lopes, E., Yang, S., Figueroa, M., Morin, R., Hirst, M., Mendez, L., Shaknovich, R., Cole, P., Bhalla, K., Gascoyne, R., Marra, M., Chiosis, G., & Melnick, A. (2010). BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. The Journal of clinical investigation, 120 12, 4569-82 . https://doi.org/10.1172/JCI42869.
Nie M, Du L, Ren W, Joung J, Ye X, Shi X, Ciftci S, Liu D, Wu K, Zhang F, Pan-Hammarström Q. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma. Cell Death Dis. 2021 Apr 28;12(5):419. doi: 10.1038/s41419-021-03695-8. PMID: 33911074; PMCID: PMC8080727.
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
